Figure 1.
Histologic, flow cytometric, clinical and mutational features of 22 patients with AITL. (A) Photomicrographs of PD-1 immunohistochemical stains from 3 patients (original magnification ×400). An example lymph node biopsy specimen from patient 16 (far left) demonstrates a proliferation of strongly PD-1–positive T cells, consistent with AITL. The middle image depicts a BM biopsy specimen from patient 14 with lymphohistiocytic aggregates containing PD-1–positive T cells, consistent with involvement by AITL. The far right image depicts a BM biopsy specimen from patient 11 that showed small lymphoid aggregates that were negative for PD-1, consistent with a reactive infiltrate, which was confirmed by FC. (B-C) Scatterplots from FC analyses of a BM involved by AITL (patient 17) (B, aqua neoplastic T-cell population) and a BM involved by MDS (patient 2) (C, red CD34+ abnormal myeloid blast population). (D) Mutations detected in the AITL of each patient (each column represents 1 patient and is annotated with the patient’s identification number). The degree of AITL involvement in each patient’s paired BM (BM T), as well as whether a MN was identified, whether FC sorting was performed, and if shared TET2 and/or DNMT3A mutations were detected in the myeloid compartment (related CH), are also indicated in the bottom rows. (E) Swimmer plot indicating the time points at which the sequenced BM biopsy was obtained, chemotherapy was initiated, or autologous or allogeneic stem cell transplant (ASCT or Allo SCT, respectively) was performed, as well as points of AITL relapse for each patient (each row represents 1 patient and is annotated with the patient's identification number). Month 0 indicates the time at which AITL was first diagnosed. Horizontal arrows indicate patients alive at last follow-up. (F-G) Comparison of the level of BM involvement by AITL (neoplastic BM T cells) to the VAFs of the TET2 and DNMT3A mutations detected in the sequenced bulk BMs among patients with shared TET2 (F) and DNMT3A (G) mutations. (H) Patients without shared TET2 mutations. Each line represents one patient and is annotated with the corresponding patient identification number.

Histologic, flow cytometric, clinical and mutational features of 22 patients with AITL. (A) Photomicrographs of PD-1 immunohistochemical stains from 3 patients (original magnification ×400). An example lymph node biopsy specimen from patient 16 (far left) demonstrates a proliferation of strongly PD-1–positive T cells, consistent with AITL. The middle image depicts a BM biopsy specimen from patient 14 with lymphohistiocytic aggregates containing PD-1–positive T cells, consistent with involvement by AITL. The far right image depicts a BM biopsy specimen from patient 11 that showed small lymphoid aggregates that were negative for PD-1, consistent with a reactive infiltrate, which was confirmed by FC. (B-C) Scatterplots from FC analyses of a BM involved by AITL (patient 17) (B, aqua neoplastic T-cell population) and a BM involved by MDS (patient 2) (C, red CD34+ abnormal myeloid blast population). (D) Mutations detected in the AITL of each patient (each column represents 1 patient and is annotated with the patient’s identification number). The degree of AITL involvement in each patient’s paired BM (BM T), as well as whether a MN was identified, whether FC sorting was performed, and if shared TET2 and/or DNMT3A mutations were detected in the myeloid compartment (related CH), are also indicated in the bottom rows. (E) Swimmer plot indicating the time points at which the sequenced BM biopsy was obtained, chemotherapy was initiated, or autologous or allogeneic stem cell transplant (ASCT or Allo SCT, respectively) was performed, as well as points of AITL relapse for each patient (each row represents 1 patient and is annotated with the patient's identification number). Month 0 indicates the time at which AITL was first diagnosed. Horizontal arrows indicate patients alive at last follow-up. (F-G) Comparison of the level of BM involvement by AITL (neoplastic BM T cells) to the VAFs of the TET2 and DNMT3A mutations detected in the sequenced bulk BMs among patients with shared TET2 (F) and DNMT3A (G) mutations. (H) Patients without shared TET2 mutations. Each line represents one patient and is annotated with the corresponding patient identification number.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal